Trendlines Group

Trendlines is a licensed incubator under the Israel Innovation Authority, not a conventional fund manager. It originates most of its portfolio companies internally, developing technology in-house, filing patents, and hiring management. The firm also maintains a publicly traded balance sheet on the Singapore Exchange, giving it permanent capital rather than operating within a traditional limited-partner fund structure.

The Singapore headquarters serves as Trendlines' commercial gateway to Asian markets. Companies initially developed in Israel are adapted for regulatory approval, manufacturing partnerships, and distribution in Asia. The dual-country footprint also allows the firm to access capital and strategic partners in both the Israeli innovation ecosystem and the broader Asian market.

Yes. While the parent company uses its own balance sheet for incubation, it has raised separate LP vehicles for specific strategies. The Trendlines Agrifood Fund, for example, attracted capital from institutional investors and strategic partners including Bayer. The firm's public listing also allows it to access equity capital markets.

Medical devices and agrifood technology constitute the two core verticals. Within medtech, the firm has backed surgical, diagnostic, and therapeutic devices; in agrifood, it has invested in aquaculture health, alternative protein processing, and crop-enhancement technologies. The firm does not typically invest in software, cybersecurity, or other sectors common in the Israeli tech landscape.

Returns come primarily through trade sales to strategics. A notable exit was ApiFix, a scoliosis-correction device company, acquired by OrthoPediatrics in 2018. The firm may also receive milestone payments and royalties from licensing arrangements, as with the recent FDA clearance milestone for ProArc Medical's prostate device.